Latest News
Ipsen reports positive Phase III results for Dysport in episodic and chronic migraine
9 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) on Thursday reported positive topline Phase III results from its BEOND migraine programme, with Dysport (abobotulinumtoxinA) meeting the primary endpoint in both ep...
Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit
9 July 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) and its partner AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Thursday that the Phase 3 CARDIO-TTRansform trial of eplontersen in adults with transthyretin-media...
Vector Science and Therapeutics names Darryl Drake Jr. president of Valor athlete and performance division
9 July 2026 - Vector Science and Therapeutics Corp (TSXV:PAIN), a pharmaceutical-grade peptide and precision drug delivery company, announced on Wednesday the appointment of Darryl Drake Jr. as president of Valor, its athlete and performance division...
Altruist Biologics' Hangzhou ADC facility approved for segmented production
9 July 2026 - Contract development and manufacturing organisation (CDMO) Altruist Biologics, a subsidiary of Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801), announced on Wednesday that its application for segmented production o...
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company's chief technical officer, Dr. Marnix Bosch, pr...